SCHEMBL29342004

SCHEMBL29342004

Cc1ccc(C)c(N2CCN(CCCC(C)C)CC2)c1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
DRD2 P14416 3/20 0.55
DRD4 P21917 3/20 0.55
DRD3 P35462 3/20 0.55
ALDH1A1 P00352 2/20 0.53
TSHR P16473 2/20 0.53
HTT P42858 2/20 0.53
TP53 P04637 4/20 0.50
MAPT P10636 2/20 0.50
POLB P06746 2/20 0.50
HTR1A P08908 1/20 0.50
ADRA1A P35348 1/20 0.50
ADRA1B P35368 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MAPK1 P28482 1/20 0.48
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7597607 0.82 MEN1 (0.67) MEN1KMT2ADRD2DRD4DRD3
SCHEMBL29341999 0.82 ADRA1B (0.55) MEN1KMT2ADRD2DRD4DRD3
SCHEMBL11392447 0.82 MEN1 (0.67) MEN1KMT2ADRD2DRD4DRD3
SCHEMBL21164677 0.82 TSHR (0.58) MEN1KMT2ADRD2DRD4DRD3
SCHEMBL13140375 0.80 MEN1 (0.64) MEN1KMT2ADRD2DRD4DRD3
SCHEMBL8370595 0.79 MEN1 (0.62) MEN1KMT2ADRD2DRD4DRD3
SCHEMBL18181904 0.77 TSHR (0.63) MEN1KMT2ADRD2DRD4DRD3
SCHEMBL29342067 0.76 HTR3E (0.53) DRD2DRD4HTTMAPTPOLB
SCHEMBL13292998 0.74 MEN1 (0.57) MEN1KMT2AALDH1A1TSHRHTT
SCHEMBL19009086 0.73 MEN1 (0.53) MEN1KMT2AALDH1A1TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239804-A1 FUROINDAZOLE DERIVATIVES AS ANTAGONISTS OR INHIBITORS OF GPR84 BAYER AKTIENGESELLSCHAFT (DE) 2024-07-18 US disclosed
US-20240239804-A1 FUROINDAZOLE DERIVATIVES AS ANTAGONISTS OR INHIBITORS OF GPR84 BAYER AKTIENGESELLSCHAFT (DE) 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239804-A1 FUROINDAZOLE DERIVATIVES AS ANTAGONISTS OR INHIBITORS OF GPR84 GPR84, GPR88, FFAR1 MEN1 699/4885KMT2A 3344/4885DRD2 1329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.